Investment Thesis
HOOKIPA exhibits severe operating losses of $15.4M against minimal $2.0M revenue, indicating unsustainable economics and rapid cash depletion despite strong cash reserves. While 118% revenue growth is encouraging, the company's viability depends entirely on successful pharmaceutical development with unclear path to profitability.
Strengths
- Revenue growth of 118.3% YoY demonstrates market traction and adoption
- Strong liquidity position with $40.3M cash reserves and 3.61x current ratio provides 2-3 year operational runway
- Minimal debt burden (0.03x D/E ratio) reduces financial distress risk and refinancing concerns
Risks
- Severe cash burn with $15.4M net loss against $2.0M revenue creates unsustainable operating model
- Operating margin of -891.9% reveals inability to generate positive returns from core operations at any scale
- Pharma development dependency creates binary outcomes; failure of pipeline candidates could render company insolvent despite cash reserves
Key Metrics to Watch
- Quarterly cash burn rate and estimated months of runway
- Clinical trial progression and regulatory milestone achievements
- Operating cash flow inflection point and path to positive unit economics
Financial Metrics
Revenue
2.0M
Net Income
-15.4M
EPS (Diluted)
$-1.23
Free Cash Flow
32.0K
Total Assets
61.3M
Cash
40.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-891.9%
Net Margin
-769.8%
ROE
-45.3%
ROA
-25.2%
FCF Margin
1.6%
Balance Sheet & Liquidity
Current Ratio
3.61x
Quick Ratio
3.61x
Debt/Equity
0.03x
Debt/Assets
44.4%
Interest Coverage
-8,937.00x
Long-term Debt
1.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T06:57:23.525810 |
Data as of: 2025-03-31 |
Powered by Claude AI